Immunocore Holdings Plc Stock Price, News & Analysis

Immunocore has announced an upcoming oral presentation of initial data from its Phase 1 study of IMC-F106C, a bispecific T cell receptor candidate targeting PRAME, at the ESMO Congress 2022. The presentation is scheduled for September 9, 2022, at 4:50 PM CEST, along with four additional poster presentations on September 10. This study represents a significant milestone in Immunocore's development of ImmTAC therapies for solid tumors, showcasing their innovative approach to cancer treatment.

Immunocore announced a $140 million private placement financing, agreeing to sell 3,733,333 shares, including 2,000,000 American Depository Shares at $37.50 each. The financing, with participation from existing investors like RTW Investments and General Atlantic, aims to fund clinical developments for oncology and infectious diseases.

Proceeds will support the advancement of tebentafusp in advanced cutaneous melanoma among other candidate programs and working capital through 2025.

Immunocore has announced the dosing of the first patient in the Phase 1 clinical trial of IMC-M113V, a T cell receptor bispecific therapy targeting HIV. This therapy aims to eliminate CD4+ cells infected with HIV, potentially leading to viral suppression without the need for lifelong antiretroviral therapy. IMC-M113V is the second candidate developed using Immunocore’s ImmTAV platform. The trial will assess its safety, antiviral activity, and pharmacokinetics in HLA-A*02:01 positive patients. The company collaborates with the Bill and Melinda Gates Foundation to ensure global access to the treatment.

Argenta has appointed Paul Fry as its new Chief Financial Officer, effective immediately, following the transition from former CFO Chris O’Donnell. This strategic move relocates the CFO role from New Zealand to London for better collaboration. Fry brings extensive financial expertise from various industries and has a track record of enhancing company valuations, including his previous role at Immunocore Limited. The CEO, Will Downie, expressed confidence in Fry's potential to drive long-term growth.

Argenta specializes in animal health R&D and manufacturing, operating globally.

Immunocore presented initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress. The study evaluated the safety and antiviral activity of IMC-I109V, a T cell receptor bispecific targeting HBsAg. Initial results showed that a single low dose led to transient declines in HBsAg levels and ALT elevations, aligning with the drug's mechanism of action. No adverse events were reported, indicating a favorable safety profile. The trial aims for a functional cure for HBV, with a focus on further patient enrollment and dose escalation.

Immunocore has appointed Siddharth Kaul to its Board of Directors, effective June 8, 2022. Kaul, a seasoned finance expert with extensive life sciences experience, previously held significant roles at Novartis and Procter & Gamble. He will contribute as a Class II director and participate in the Audit and Remuneration committees. This appointment aligns with Immunocore's focus on the commercial rollout of its lead product, KIMMTRAK, for treating metastatic uveal melanoma and enhancing its oncology and infectious disease pipeline.

Immunocore Holdings has received marketing authorization for KIMMTRAK® (tebentafusp) from the UK, Australia, and Canada to treat unresectable or metastatic uveal melanoma. This therapy is the first approved treatment for this rare form of melanoma, displaying a statistically significant overall survival benefit in clinical trials. KIMMTRAK showed a median overall survival of nearly 22 months with a hazard ratio of 0.51. Following approvals in the US and EU, this new authorization marks a significant milestone for both the company and patients.

Immunocore presented new data on KIMMTRAK (tebentafusp-tebn) at the 2022 ASCO Annual Meeting. The Phase 1b trial showed a one-year overall survival (OS) of about 75% in heavily pre-treated metastatic cutaneous melanoma (mCM), surpassing the 55% benchmark. The study also confirmed that corticosteroids for adverse events did not significantly impact efficacy. Immunocore plans to initiate a randomized study by year-end to further evaluate tebentafusp in mCM.

Immunocore has entered a clinical trial collaboration with Sanofi to evaluate SAR444245, a PEGylated IL-2 candidate, in combination with KIMMTRAK for patients with metastatic cutaneous melanoma. The study is part of Sanofi's ongoing Phase 1/2 trial. Sanofi will handle clinical development costs, while Immunocore will supply KIMMTRAK. KIMMTRAK has FDA approval for unresectable or metastatic uveal melanoma, and upcoming trials are planned combining it with anti-PD1 therapy. This collaboration could enhance treatment prospects for patients with significant unmet needs.